These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 29177689

  • 1. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S.
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [Abstract] [Full Text] [Related]

  • 2. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N, Takahashi Y, Matsuda N, Tsunoda H, Yoshida A, Suzuki K, Nakamura S, Yamauchi H.
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [Abstract] [Full Text] [Related]

  • 3. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
    Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marmé F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching PA, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C.
    Breast Cancer Res; 2024 Sep 24; 26(1):138. PubMed ID: 39317942
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X.
    Clin Breast Cancer; 2020 Feb 24; 20(1):19-24. PubMed ID: 31806448
    [Abstract] [Full Text] [Related]

  • 5. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y.
    Breast Cancer Res Treat; 2018 Feb 24; 168(1):135-145. PubMed ID: 29168063
    [Abstract] [Full Text] [Related]

  • 6. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M, Sarma YS.
    J Cancer Res Ther; 2020 Feb 24; 16(6):1419-1425. PubMed ID: 33342807
    [Abstract] [Full Text] [Related]

  • 7. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.
    Breast Cancer; 2015 May 24; 22(3):308-16. PubMed ID: 23771556
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 May 24; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 9. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM, Harhay MO, Zhang P, Ugras S.
    Ann Surg Oncol; 2018 Nov 24; 25(12):3535-3540. PubMed ID: 29981025
    [Abstract] [Full Text] [Related]

  • 10. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
    Schettini F, Nucera S, Brasó-Maristany F, De Santo I, Pascual T, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rivera P, Rodríguez AB, Martínez-Sáez O, Ganau S, Sanfeliu E, González-Farre B, Vidal Losada MJ, Adamo B, Cebrecos I, Mension E, Oses G, Jares P, Vidal-Sicart S, Mollà M, Muñoz M, Prat A.
    ESMO Open; 2024 Jul 24; 9(7):103619. PubMed ID: 38943737
    [Abstract] [Full Text] [Related]

  • 11. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2-) Breast Cancer.
    Hu Y, Wang S, Ding N, Li N, Huang J, Xiao Z.
    Clin Breast Cancer; 2020 Aug 24; 20(4):e403-e409. PubMed ID: 32201163
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Takahashi Y, Iwamoto T, Suzuki Y, Kajiwara Y, Hatono M, Tsukioki T, Kawada K, Kochi M, Ikeda H, Shien T, Taira N, Matsuoka J, Doihara H, Toyooka S.
    Clin Breast Cancer; 2020 Apr 24; 20(2):117-124.e4. PubMed ID: 31570267
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, Hartavi M, Kurt E, Evrensel T.
    J BUON; 2015 Apr 24; 20(1):45-9. PubMed ID: 25778295
    [Abstract] [Full Text] [Related]

  • 14. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
    Tang L, Jiang L, Shu X, Jin Y, Yu H, Liu S.
    Sci Rep; 2024 May 23; 14(1):11761. PubMed ID: 38783028
    [Abstract] [Full Text] [Related]

  • 15. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ, Morrow M, Modi S, Zhang Z, Krause K, Siu C, McCormick B, Powell SN, Ho AY.
    Ann Surg Oncol; 2015 Dec 23; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [Abstract] [Full Text] [Related]

  • 16. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
    Teleki I, Krenacs T, Szasz MA, Kulka J, Wichmann B, Leo C, Papassotiropoulos B, Riemenschnitter C, Moch H, Varga Z.
    BMC Cancer; 2013 Feb 02; 13():50. PubMed ID: 23374644
    [Abstract] [Full Text] [Related]

  • 17. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M, Tsunoda H, Yagata H, Hayashi N, Yoshida A, Morishita E, Takei J, Suzuki K, Yamauchi H.
    Clin Breast Cancer; 2018 Apr 02; 18(2):128-134. PubMed ID: 28843513
    [Abstract] [Full Text] [Related]

  • 18. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, Filipits M, Austrian Breast and Colorectal Cancer Study Group.
    Eur J Cancer; 2020 Jul 02; 134():99-106. PubMed ID: 32502940
    [Abstract] [Full Text] [Related]

  • 19. Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    Woo J, Oh SJ, Song JY, Chae BJ, Choi JE, Lee J, Park HK, Korean Breast Cancer Society, Lim W.
    BMC Cancer; 2021 May 31; 21(1):647. PubMed ID: 34059020
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.
    Breast Cancer; 2015 Mar 31; 22(2):185-91. PubMed ID: 23645542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.